Assessment of the minimum clinically important difference in quality of life in schizophrenia measured by the Quality of Well-Being Scale and disease-specific measures

Psychiatry Research

Volumn 209, Issue 3, 2013, Pages 291-296

  Thwin, Soe Soe ^a,b   Hermes, Eric ^c   Lew, Robert ^a,b   Barnett, Paul ^d   Liang, Matthew ^a   Valley, Danielle ^a   Rosenheck, Robert ^c,e  

^a VA BOSTON HEALTHCARE SYSTEM   (United States)

^b BOSTON UNIVERSITY   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^e VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Clinical trials; Equipercentile Linkage; Minimum clinically important differences; Quality of life; Schizophrenia; Utility

Indexed keywords

ADULT; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COMPARATIVE EFFECTIVENESS; CONCURRENT VALIDITY; CORRELATION ANALYSIS; EFFECT SIZE; FEMALE; HEINRICH CARPENTER QUALITY OF LIFE SCALE; HOSPITAL PATIENT; HUMAN; LENERT UTILITY MEASURE SCALE; MAJOR CLINICAL STUDY; MALE; MINIMUM CLINICALLY IMPORTANT DIFFERENCE; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; PSYCHOMETRY; QUALITY OF LIFE; QUALITY OF WELL BEING SCALE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; STATISTICAL CONCEPTS; VETERAN;

CLINICAL TRIALS; EQUIPERCENTILE LINKAGE; MINIMUM CLINICALLY IMPORTANT DIFFERENCES; QUALITY OF LIFE; SCHIZOPHRENIA; UTILITY;

ADULT; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TIME FACTORS; VETERANS;

EID: 84885471449     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2013.01.016     Document Type: Article

References (30)

1. Cramer J., Rosenheck R., Xu W., Henderson W., Thomas J., Charney D. Department of Veterans Affairs Cooperative Study Group on Clozapine in refractory schizophrenia. Detecting improvement in quality of life and symptomatology in schizophrenia. Schizophrenia Bulletin 2001, 27(2):227-234.
2. First M.B., Spitzer R.L., Gibbon M.B., Williams J.B. Structured clinical interview for Axes I and II DSM IV disorders-Patient Edition (SCID-I/P) 1996, Biometrics Research Institute, New York State Psychiatric Institute, New York.
3. Gold M., Franks P., Erickson P. Assessing the health of the nation. The predictive validity of a preference-based measure and self-rated health. Medical Care 1996, 34(2):163-177.
4. Guy, W., 1976. Clinical Global Impressions (CGI). In: ECDEU Assessment Manual for Psychopharmacology. National Institute of Mental Health, Rockville, MD, pp. 534-537.
5. Heinrichs D.W., Hanlon E.T., Carpenter W.T. The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin 1984, 10(3):388-398.
6. Hermes E., Sokoloff D., Stroup T.S., Rosenheck R. The minimum clinically important difference in the positive and negative syndrome scale using data from the CATIE Schizophrenia Trial. Journal of Clinical Psychiatry 2012, 73(4):526-532.
7. Jaeschke R., Singer J., Guyatt G.H. Measurement of health status. Ascertaining the minimal clinically important difference. Controlled Clinical Trials 1989, 4:407-415.
8. Kaplan R.M. Quality of life assessment for cost/utility studies in cancer. Cancer Treatment Reviews 1993, 19(Suppl A):85-96.
9. Kaplan R.M., Anderson J.P. The general health policy model: an integrated approach. Quality of Life and Pharmacoeconomics in Clinical Trials 1996, 309-322. Lippincott-Raven, Philadelphia. 2nd ed. B. Spilker (Ed.).
10. Kaplan R.M., Ries A.L., Reilly J., Mohsenifar Z. National Emphysema Treatment Trial Research Group. Measurement of health-related quality of life in the national emphysema treatment trial. Chest 2004, 126(3):781-789.
11. Kaplan R.M. The minimally clinically important difference in generic utility-based measures. COPD: Journal of Chronic Obstructive Pulmonary Disease 2005, 2(1):91-97.
12. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987, 13(2):261-276.
13. Kasckow J.W., Twamley E., Mulchahey J.J., Carroll B., Sabai M., Strakowski S.M., Patterson T., Jeste D.V. Health-related quality of well-being in chronically hospitalized patients with schizophrenia: comparison with matched outpatients. Psychiatry Research 2001, 103(1):69-78.
14. Kolen M.J., Brennan R.L. Test Equating. Methods and Practices 1995, Springer, New York, pp. 36-46.
15. Liang M.H., Lew R.A., Stucki G., Fortin P.R., Daltroy L.H. Measuring clinically important changes with patient-oriented questionnaires. Medical Care 2002, 40(II):45-51.
16. Lenert L.A., Rupnow M.F.T., Elnitsky C. Application of a disease-specific mapping function to estimate utility gains with effective treatment of schizophrenia. Health and Quality of Life Outcomes 2005, 3:57.
17. Leucht S., Kane J.M., Kissling W., Hamann J., Etschel E., Engel R.R. What does the PANSS mean?. Schizophrenia Research 2005, 79:231-238.
18. Levine S.Z., Rabinowitz J., Engel R., Etschel E., Leucht S. Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI. Schizophrenia Research 2008, 98(1-3):318-322.
19. Lydick E., Epstein R.S. Interpretation of quality of life changes. Quality of Life Research 1993, 2(3):221-226.
20. Patterson T.L., Kaplan R.M., Grant I., Semple S.J., Moscona S., Koch W.L., Harris M.J., Jeste D.V. Quality of well-being in late-life psychosis. Psychiatry Research 1996, 63:169-181.
21. Patterson T.L., Shaw W., Semple S.J., Moscona S., Harris M.J., Kaplan R.M., Grant I., Jeste D.V. Health-related quality of life in older patients with schizophrenia and other psychoses: relationships among psychosocial and psychiatric factor. International Journal of Geriatric Psychiatry 1997, 12:452-461.
22. Pouchot J., Kherani R., Brant R., Lacaille D., Lehman A., Ensworth S., Kopec J., Esdaile J.M., Liang M.H. Fatigue in rheumatoid arthritis: determination of the minimal clinically important difference for seven fatigue measures. Journal of Clinical Epidemiology 2008, 61:705-713.
23. Price L.R., Lurie A., Wilkins C. Computer program exchange: EQUIPERCENT: A SAS program for calculating equivalent scores using. Applied Psychological Measurement 2001, 25(4):332.
24. Pyne J.M., Sullivan G., Kaplan R., Williams K. Comparing the sensitivity of generic effectiveness measures with symptom improvement in persons with schizophrenia. Medical Care 2003, 41(2):208-217.
25. Rabinowitz J., Mehnert A., Eerdekens M. To what extent do the PANSS and CGI-S overlap?. Journal of Clinical Psychopharmacology 2006, 26(3):303-307.
26. Rosenheck R.A., Swartz M., McEvoy J., Stroup T.S., Davis S., Keefe R.S.E., Hsiao J., Lieberman J. Changing perspectives on second generation antipsychotics: reviewing the cost-effectiveness component of the CATIE trial. Expert Review of Pharmacoeconomics and Outcomes Research 2007, 7(2):103-111.
27. Rosenheck R.A., Krystal J.H., Lew R., Barnett P.G., Fiore L., Valley D., Thwin S.S., Vertrees J.E., Liang M.H. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. New England Journal of Medicine 2011, 364:842-851.
28. Ruskin P.E., Reed S., Kumar R., Kling M.A., Siegel E., Rosen M., Hauser P. Reliability and acceptability of psychiatric diagnosis via telecommunication and audiovisual technology. Psychiatric Services 1998, 49(8):1086-1088.
29. Schennach-Wolff R., Obermeier M., Seemüller F., Jäger M., Schmauss M., Laux G., Pfeiffer H., Naber D., Schmidt L.G., Gaebel W., Klosterkötter J., Heuser I., Maier W., Lemke M.R., Rüther E., Klingberg S., Gastpar M., Engel R.R., Möller H.J., Riedel M. Does clinical judgment of baseline severity and changes in psychopathology depend on the patient population? Results of a CGI and PANSS linking analysis in a naturalistic study. Journal of Clinical Psychopharmacology 2010, 6:726-731.
30. Valenstein M., Kavanagh J., Lee T., Reilly P., Dalack G.W., Grabowski J., Smelson D., Ronis D.L., Ganoczy D., Woltmann E., Metreger T., Wolschon P., Jensen A., Poddig B., Blow F.C. Using a pharmacy-based intervention to improve antipsychotic adherence among patients with serious mental illness. Schizophrenia Bulletin 2011, 37(4):727-736.